MC38-OVA Syngeneic Model Service for Colon Cancer

The MC38-OVA syngeneic model of colon cancer equips the immunogenic MC38 adenocarcinoma with a defined model antigen—chicken ovalbumin—enabling antigen-specific T-cell responses to be tracked with precision in fully immunocompetent mice. Alfa Cytology delivers the complete MC38-OVA workflow—construct-verified cell banking, flank implantation, OT-I/OT-II adoptive-transfer designs, checkpoint and vaccine intervention schedules, and tetramer-based endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of MC38-OVA Syngeneic Model for Colon Cancer

MC38-OVA is the antigen-defined sibling of the classic MC38 line: the mismatch-repair-deficient, hypermutated C57BL/6 colon adenocarcinoma is stably engineered to express full-length chicken ovalbumin, whose two dominant epitopes slot perfectly into the best-characterized T-cell toolkit in immunology—SIINFEKL (OVA257–264) presented on H-2K^b to OT-I CD8 T cells, and ISQAVHAAHAEINEAGR (OVA323–339) on I-A^b to OT-II CD4 T cells. Because OT-I (JAX 003831) and OT-II (JAX 004194) transgenic strains are available on congenic CD45.1 or Thy1.1 backgrounds, cohorts of naive, antigen-specific T cells can be adoptively transferred and followed as they proliferate, differentiate, infiltrate and exhaust inside a real tumor—something no human tumor model permits. The detection toolbox is equally mature: H-2K^b–SIINFEKL tetramers quantify antigen-specific T cells, the 25-D1.16 antibody directly visualizes peptide–MHC complexes on tumor tissue, and the B3Z hybridoma reports presentation in vitro. Constructs vary by laboratory—some versions co-express EGFP at equal copy number, others carry neomycin-selected expression cassettes—so construct verification is a standing prerequisite.

Fig 1. OVA antigen capture by erythroid progenitor cells in the MC38-OVA syngeneic model — OVA expression validation on MC38-OVA cells, 25-D1.6 (OVA-MHC I tetramer) uptake in tumor tissue versus spleen and lymph node, quantifying tumor-associated antigen presentation and CD8+ T cell tolerance induction. (Fan, Xue, et al., 2024)

In vivo the model runs on a familiar template: one million cells in the flank, tumors palpable within five to seven days, and—in the classic adoptive-cell-therapy format—two to five million OT-I cells delivered intravenously around day five to seven, after which growth, rejection or equilibrium plays out under the sponsor’s intervention. The system’s publication record is broad and deep: checkpoint blockade has been shown to invigorate OT-I cells within MC38-OVA tumors; regulatory studies of antigen presentation have used it to expose how lncRNA EPIC1, the deubiquitinase USP22 or the oncoprotein SND1 dampen MHC-I display; dendritic-cell and DC-exosome vaccines have been benchmarked against it; DNA vaccines encoding tandem neoantigen strings have used OVA as the reporter epitope; and recent work showed tumor-associated macrophages acquiring and presenting its antigen—cross-dressing—to T cells. Three caveats discipline its use: ovalbumin is a foreign model antigen, so translation to human tumor antigens requires care; expression can drift or be lost under immune pressure, demanding maintenance of selection and pre-implant verification; and its defined antigen makes it more immunogenic than parental MC38, so rejection kinetics run faster and windows are correspondingly shorter.

Cell Line Information: MC38-OVA

Key characteristics of MC38-OVA and its companion reagents are summarized below.

Our Services

With in vivo oncology and T-cell-biology specialists guiding each stage and flow cytometry, tetramer staining and digital pathology in-house, Alfa Cytology configures every MC38-OVA engagement around the sponsor’s antigen-specific question—controlling construct and expression stability, coordinating OT-I/OT-II logistics, and pairing interventions with tetramer-based readouts for clean, decision-grade preclinical data.

Workflow of MC38-OVA Syngeneic Model Construction

Construction of the MC38-OVA syngeneic model is an implantation-plus-adoptive-transfer workflow whose quality rests on verified antigen expression, well-matched hosts and standardized schedules. A standard engagement proceeds as follows:

1. Construct verification and cell qualification: MC38-OVA stocks are cleared by mycoplasma PCR and identity checks, with OVA expression confirmed by Western blot and surface SIINFEKL–H-2K^b staining (25-D1.16); the selection antibiotic is maintained through expansion to guard against antigen loss.
2. Prepare recipients: C57BL/6 mice (6–8 weeks; wild-type, OT-I/OT-II transgenic or congenically marked depending on design; Rag2^−/− where pure ACT is required) complete acclimation and health screening.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 1 × 10⁷/mL for a 100 µL dose).
4. Implant: 1 × 10⁶ MC38-OVA cells are injected subcutaneously into the flank with consistent anatomical positioning for reproducible caliper measurement.
5. Adoptive transfer where designed: around day 5–7, once tumors are palpable, 2–5 × 10⁶ OT-I (or OT-II) cells are administered intravenously, with optional CFSE or congenic labeling for proliferation and persistence tracking.
6. Randomize, dose and follow: animals are grouped by tumor volume and body weight; test articles (checkpoint agents, vaccines, adjuvants) are dosed on schedule; tumors are measured two to three times weekly, with optional serial blood draws for tetramer-based T-cell monitoring.
7. Terminate and analyze: tumors are resected and weighed; tumor-infiltrating lymphocytes are analyzed by flow cytometry with H-2K^b–SIINFEKL tetramers and activation/exhaustion panels; sections are stained with 25-D1.16 and CD3; splenocytes undergo restimulation ICS or ELISPOT; tissues enter histopathology and molecular analysis.

Fig 2. MC38-OVA Syngeneic Model construction workflow.

Case Study-MC38-OVA Syngeneic Model Development

Alfa Cytology maintains an active preclinical case-study file on the MC38-OVA platform: establishment-phase construct verification and expression-stability testing, in vivo growth and rejection kinetics with and without OT-I transfer, vaccine- and checkpoint-based intervention studies with antigen-specific monitoring, and endpoint analyses combining tetramer staining, 25-D1.16 immunohistochemistry and TIL phenotyping. Representative growth curves, T-cell tracking datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

An antigen-defined model succeeds or fails on expression stability and T-cell logistics, and both are where Alfa Cytology concentrates its effort:

• Construct-aware banking with Western blot and 25-D1.16 verification plus enforced selection maintenance.
• Coordinated access to OT-I, OT-II and congenic C57BL/6 hosts, including Rag2^−/− designs for pure ACT readouts.
• In-house tetramer staining and multiparameter flow cytometry for antigen-specific TIL quantification.
• Familiarity across the model’s documented uses, from vaccine benchmarking to antigen-presentation biology.
• Checkpoint-combination schedules validated against OT-I invigoration endpoints.
• Defined rejection-kinetics planning so compressed windows are anticipated, not discovered.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the MC38-OVA syngeneic colon cancer model for your next preclinical program? Reach out to us with your antigen-specific design, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, OT-I/OT-II coordination and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.